EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Palmitoylethanolamide in Postmenopausal Metabolic Syndrome: Current Evidence and Clinical Perspectives

Alessandro Medoro iD, Sergio Davinelli iD, Federica Fogacci iD, Stefania Alfieri, Domenico Tiso iD, Arrigo F G Cicero iD, Giovanni Scapagnini iD

Nutrients · 2024

DOI: 10.3390/nu16244313 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, 2024. Verfasst von Alessandro Medoro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Health Sciences "V.Tiberio", University of Molise, 86100 Campobasso, Italy. Hauptthemen laut MEDLINE: Metabolic Syndrome, Palmitic Acids, Ethanolamines, Amides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “F.F.I.N—Functional Foods Italy Network” (POS TR5—Piano Operativo Salute Traiettoria 5), Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Menopause leads to a decline in estrogen levels, resulting in significant metabolic alterations that increase the risk of developing metabolic syndrome—a cluster of conditions including central obesity, insulin resistance, dyslipidemia, and hypertension. Traditional interventions such as hormone replacement therapy carry potential adverse effects, and lifestyle modifications alone may not suffice for all women. This review explores the potential role of palmitoylethanolamide (PEA), an endogenous fatty acid amide, in managing metabolic syndrome during the postmenopausal period. PEA primarily acts by activating peroxisome proliferator-activated receptor-alpha (PPAR-α), influencing lipid metabolism, energy homeostasis, and inflammation. Evidence indicates that PEA may promote the browning of white adipocytes, enhancing energy expenditure and reducing adiposity. It also improves lipid profiles by boosting fatty acid oxidation and decreasing lipid synthesis, potentially lowering low-density lipoprotein cholesterol and triglyceride levels while increasing high-density lipoprotein cholesterol. Additionally, the anti-inflammatory properties of PEA enhance insulin sensitivity by reducing pro-inflammatory cytokines that interfere with insulin signaling. PEA may aid in weight management by influencing appetite regulation and improving leptin sensitivity. Furthermore, its neuroprotective effects may address the mood disturbances and cognitive decline associated with menopause. Given these multifaceted biological activities and a favorable safety profile, PEA may represent a promising non-pharmacological supplement for managing metabolic syndrome in postmenopausal women. However, further large-scale clinical studies are necessary to establish its efficacy, optimal dosing, and long-term safety. If validated, PEA could become an integral part of strategies to improve metabolic and neuropsychological health outcomes in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromePalmitic AcidsEthanolaminesAmidesPostmenopauseHumansFemaleInsulin ResistanceLipid MetabolismEnergy Metabolism

Stichwörter der Autor:innen

PPAR-αappetite regulationinsulin resistancelifestyle interventionsmenopausemetabolic syndromepalmitoylethanolamideweight management

Substanzen

palmidrolPalmitic AcidsEthanolaminesAmides

Autor:innen und Institutionen

  • Department of Medicine and Health Sciences "V.Tiberio", University of Molise, 86100 Campobasso, Italy.
  • Hypertension and Cardiovascular Risk Research Unit, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy.
  • Italian Nutraceutical Society (SINut), 40138 Bologna, Italy.
  • Centro Mediprò, 40068 San Lazzaro di Savena, Italy.
  • Clinical Nutrition, "Villa Maria" Hospital, 47921 Rimini, Italy.
  • Cardiovascular Medicine Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

ORCID-Profile: Alessandro Medoro, Sergio Davinelli, Federica Fogacci, Domenico Tiso, Arrigo F G Cicero, Giovanni Scapagnini

Förderung

  • “F.F.I.N—Functional Foods Italy Network” (POS TR5—Piano Operativo Salute Traiettoria 5)
  • Italian Ministry of Health

Zitieren

APA

Medoro, A., Davinelli, S., Fogacci, F., Alfieri, S., Tiso, D., Cicero, A. F. G., & Scapagnini, G. (2024). Palmitoylethanolamide in Postmenopausal Metabolic Syndrome: Current Evidence and Clinical Perspectives. Nutrients. https://doi.org/10.3390/nu16244313

Vancouver

Medoro A, Davinelli S, Fogacci F, Alfieri S, Tiso D, Cicero AFG, et al. Palmitoylethanolamide in Postmenopausal Metabolic Syndrome: Current Evidence and Clinical Perspectives. Nutrients. 2024. doi:10.3390/nu16244313

BibTeX
@article{Medoro2024,
  author = {Medoro, Alessandro and Davinelli, Sergio and Fogacci, Federica and Alfieri, Stefania and Tiso, Domenico and Cicero, Arrigo F G and Scapagnini, Giovanni},
  title = {Palmitoylethanolamide in Postmenopausal Metabolic Syndrome: Current Evidence and Clinical Perspectives},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16244313}
}
Kostenlos starten →